Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1

Status

Completed 5Recruiting 4Not yet recruiting 2Active not recruiting 2Unknown 1Enrolling by invitation 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Plasma cell 1Other hematologic neoplasm 1CNS 1

Conditions

Lymphoma 1600Precursor Cell Lymphoblastic Leukemia-Lymphoma 1282Lymphoma, Non-Hodgkin 1231Leukemia, Lymphocytic, Chronic, B-Cell 1090Lymphoma, Follicular 979Lymphoma, Large B-Cell, Diffuse 853Leukemia 790Hodgkin Disease 777Lymphoma, Mantle-Cell 675Leukemia, Myeloid, Acute 540Burkitt Lymphoma 507Lymphoma, B-Cell, Marginal Zone 490Multiple Myeloma 483Myelodysplastic Syndromes 371Lymphoma, Large-Cell, Immunoblastic 366Recurrence 363Lymphoma, T-Cell, Cutaneous 313Neoplasms 309Waldenstrom Macroglobulinemia 307Lymphoma, Large-Cell, Anaplastic 254Mycosis Fungoides 252Lymphoma, B-Cell 231Sezary Syndrome 229Blast Crisis 210Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 208Myeloproliferative Disorders 205Leukemia, Myelogenous, Chronic, BCR-ABL Positive 189Neoplasms, Plasma Cell 188Leukemia, Myeloid, Accelerated Phase 186Leukemia, Myeloid, Chronic-Phase 179

Interventions

siltuximab 1axicabtagene ciloleucel 1Neuropsychological Tests 1Magnetic Resonance Spectroscopy 1Interleukin 1 Receptor Antagonist Protein 1Gelsolin 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Cytokine Release Syndrome × Lymphoid × Clear all
NCT04975555 2026-06-03

Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy

University of Alabama at Birmingham

Phase 2 Completed
24 enrolled 8 charts
LymphoidOther hematologic neoplasmPlasma cell

Cytokine Release Syndrome, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04150913 2025-11-25

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Massachusetts General Hospital

Phase 2 Completed
15 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Neurotoxicity Syndromes

NCT04466098 2025-01-29

Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)

Masonic Cancer Center, University of Minnesota

Phase 2 Completed
8 enrolled 21 charts
Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Respiratory Distress Syndrome

NCT05510596 2024-08-09

MR-ICANS

University Hospital, Montpellier

Phase NA Completed
25 enrolled
Lymphoid

Cytokine Release Syndrome, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT04358406 2023-11-28

Rhu-pGSN for Severe Covid-19 Pneumonia

BioAegis Therapeutics Inc.

Phase 2 Completed
64 enrolled 17 charts
Lymphoid

Cytokine Release Syndrome, COVID-19, Lymphoma, Follicular, Pneumonia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡